English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Interleukin-15 (IL-15) is a pleiotropic cytokine that plays a key role in the regulation of both innate and adaptive immune responses. It promotes the survival, proliferation, activation and maintenance of natural killer and CD8+ T cells. It also stimulates the function of neutrophils, macrophages and dendritic cells, and could therefore be a potential cytokine for cancer immune therapy. The therapeutic effects of cytokines are related to their expression levels. In this study, we investigated an amplified IL-15 expression plasmid vector, pHi2-spIL15-CMV-tat, and a carcinoembryonic antigen (CEA)-positive tumor-specific amplified IL-15 expression plasmid vector, pHi2-spIL15-CEA-tat. In pHi2-spIL15-CMV-tat, IL-15 expression was driven by HIV2 LTR, which was transactivated by CMV promoter-controlled expression of HIV tat. In addition, the native IL-15 signal peptide was replaced by the IL-2 signal peptide to enhance its secretion. A significant amount of IL-15 expression was achieved when transfected into tumor cells in vitro. In order to target IL-15 expression in CEA-positive cells, the CEA promoter positively-controlled IL-15 expression plasmid vector pHi2-spIL15-CEA-tat was constructed by replacing the CMV with the CEA promoter. Efficient and targeted IL-15 expression was achieved in CEA-positive tumor cells by pHi2-spIL15-CEA-tat.

Amplified interleukin-15 expression vectors for cancer immunogene therapy